Search

Displaying results 921 - 930 of 1764 in total
  1. Drug

    ZM-39923

    go.drugbank.com/drugs/DB17064
    Experimental

    ZM-39923 is a small molecule that inhibits Janus kinase and human tissue transglutaminase (TGM2).[A253177]

    Salts: ZM-39923 hydrochloride
  2. Drug

    CM-4307

    go.drugbank.com/drugs/DB15414
    Investigational

    CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).

  3. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

  4. Drug

    Dilanubicel

    go.drugbank.com/drugs/DB18722
    Investigational

    Dilanubicel consists of ex vivo expanded hematopoietic stem and progenitor cells.

  5. Drug

    Tyrosine

    go.drugbank.com/drugs/DB00135
    ApprovedInvestigationalNutraceutical

    Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

    Mixtures: Clinimix E, Clinimix E
  6. Drug

    Nelotanserin

    go.drugbank.com/drugs/DB12555
    Investigational

    It increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM or dream sleep. … Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder.

  7. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  8. Drug

    Fructose

    go.drugbank.com/drugs/DB04173
    ApprovedInvestigational

    Mixtures: Formula EmProducts: ESAFOSFINA (5 GM)
  9. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.

  10. Drug

    Light green SF yellowish

    go.drugbank.com/drugs/DB11183
    Approved

    The maximum absorption of light green SF yellowish is at 630 (422) nm.